Combining checkpoint inhibitors with other treatments, such as chemotherapy, radiation, or other immunotherapies, is an area of active research. Combination therapies aim to enhance the overall effectiveness of treatment by targeting cancer through multiple mechanisms. Early results from these trials are encouraging, showing improved response rates and survival outcomes.
